Ocular Therapeutix Inc (OCUL)
6.21
+0.34
(+5.88%)
USD |
NASDAQ |
May 03, 15:53
Ocular Therapeutix 1 Year Total Returns (Daily): -1.76% for May 2, 2024
1 Year Total Returns (Daily) Chart
Historical 1 Year Total Returns (Daily) Data
| Date | Value |
|---|---|
| May 02, 2024 | -1.76% |
| May 01, 2024 | -18.77% |
| April 30, 2024 | -23.55% |
| April 29, 2024 | -22.58% |
| April 26, 2024 | -21.05% |
| April 25, 2024 | -28.81% |
| April 24, 2024 | -25.08% |
| April 23, 2024 | -22.24% |
| April 22, 2024 | -21.07% |
| April 19, 2024 | -10.31% |
| April 18, 2024 | 2.27% |
| April 17, 2024 | 30.69% |
| April 16, 2024 | 48.10% |
| April 15, 2024 | 48.29% |
| April 12, 2024 | 57.28% |
| April 11, 2024 | 58.32% |
| April 10, 2024 | 53.59% |
| April 09, 2024 | 58.33% |
| April 08, 2024 | 54.84% |
| April 05, 2024 | 71.54% |
| April 04, 2024 | 69.06% |
| April 03, 2024 | 61.26% |
| April 02, 2024 | 60.91% |
| April 01, 2024 | 64.90% |
| March 28, 2024 | 79.49% |
| Date | Value |
|---|---|
| March 27, 2024 | 81.13% |
| March 26, 2024 | 86.99% |
| March 25, 2024 | 91.26% |
| March 22, 2024 | 95.67% |
| March 21, 2024 | 97.86% |
| March 20, 2024 | 103.7% |
| March 19, 2024 | 95.56% |
| March 18, 2024 | 90.32% |
| March 15, 2024 | 85.49% |
| March 14, 2024 | 81.57% |
| March 13, 2024 | 91.04% |
| March 12, 2024 | 90.76% |
| March 11, 2024 | 99.79% |
| March 08, 2024 | 77.26% |
| March 07, 2024 | 76.51% |
| March 06, 2024 | 94.09% |
| March 05, 2024 | 84.94% |
| March 04, 2024 | 84.09% |
| March 01, 2024 | 77.10% |
| February 29, 2024 | 66.56% |
| February 28, 2024 | 64.74% |
| February 27, 2024 | 66.11% |
| February 26, 2024 | 67.23% |
| February 23, 2024 | 63.52% |
| February 22, 2024 | 60.07% |
Total Return Definition
The Total return is the change in price over a specific period of time that includes dividends and distributions paid.
1 Year Total Returns (Daily) Range, Past 5 Years
-81.37%
Minimum
Apr 29 2022
465.3%
Maximum
Dec 15 2020
33.44%
Average
2.56%
Median
Jan 24 2024
1 Year Total Returns (Daily) Benchmarks
| Amgen Inc | 21.94% |
| Assertio Holdings Inc | -82.56% |
| CytomX Therapeutics Inc | 172.1% |
| EyePoint Pharmaceuticals Inc | 207.1% |
| Regeneron Pharmaceuticals Inc | 17.43% |